ITM Isotope Technologies Munich SE

General information
ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Bavaria
Germany

Contact person: Ben Orzelek, Head of Investor Relations & Treasury
Company main phone: +49 (89) 32989866000
Company main fax:  +49 (89) 32989866061
Website:  https://itm-radiopharma.com
Year founded:2004
Source of foundation:Independent foundation
Corporate description / mission:
ITM Isotope Technologies Munich, a radiopharmaceutical biotech company, is focused on developing new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company’s radioisotopes with a range of targeting molecules.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Antibodies
  • Peptides
  • Other
Primary therapeutic areas:
  • Diseases of the ear / otology
  • Neoplasms / cancer / oncology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:10
Phase III:3
Description of products:
ITM-11
ITM-63
ITM-14D
ITM-22
ITM-24D, etc.
Collaborations & Clients
Partnering strategy / collaborations:
The company is always seeking innovative drug discovery partnerships, ideally fusing their target know-how with their leading radioisotope platform technologies to develop next generation diagnostic and therapeutic agents that will help fight serious and difficult to treat cancer diseases.
X